NervGen Pharma (NGEN) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about NGEN filings

Are insiders buying or selling NervGen Pharma Corp. (NGEN) stock?

Neither. NervGen Pharma Corp. (NGEN) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded NGEN recently?

None. No member of Congress disclosed a NGEN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this NGEN smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

7 funds hold a position.

Questions about NGEN filings

Are insiders buying or selling NervGen Pharma Corp. (NGEN) stock?

Neither. NervGen Pharma Corp. (NGEN) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded NGEN recently?

None. No member of Congress disclosed a NGEN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this NGEN smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

The latest quarter is still settling.

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 13, 2026	-$0.37est. -$0.09	-$0.28miss	Not on file	Not on file
Mar 31, 2026Reported May 18, 2026	-$0.07est. -$0.06	-$0.01miss	CAD 0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 31, 2026	-$0.27est. -$0.07	-$0.20miss	CAD 0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 25, 2025	-$0.04est. -$0.04	+$0.00beat	Not on file	Not on file
Jun 30, 2025Reported Aug 26, 2025	-$0.09est. -$0.06	-$0.03miss	Not on file	Not on file
Mar 31, 2025Reported May 15, 2025	-$0.04est. -$0.06	+$0.02beat	Not on file	Not on file
Sep 30, 2024Reported Nov 14, 2024	-$0.05Reported	No estimate	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.39
High: $1.41
Low: $1.32
Prev close: $1.40
52-wk high: $6.30
52-wk low: $1.28
Mkt cap: $175.3M
ROE: -96.8%
Beta: 0.78
P/B: 11.8x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $175M

Valuation

P/B11.82

Quality

Operating margin0.0%
ROE-96.8%
ROA-38.0%

Growth

Beta0.78

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

35balanced

20D volatility

49%annualized

52-week range

$1.33

$1.28$6.30

20D support

$1.28recent floor

20D resistance

$1.66recent ceiling

Returns

5D +0.8%20D -18.4%60D -20.8%

Price vs moving averages

SMA20 -7.7%SMA50 -25.2%SMA200 -50.9%

Volume pace

0.97xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 12, 2026

Not on file

No estimate

Not on file

Jun 30, 2026Aug 13, 2026

-$0.37est. -$0.09

-$0.28

Not on file

Mar 31, 2026May 18, 2026

-$0.07est. -$0.06

-$0.01

CAD 0.00Yahoo Finance

No year-ago quarter

Dec 31, 2025Mar 31, 2026

-$0.27est. -$0.07

-$0.20

CAD 0.00Yahoo Finance

No year-ago quarter

Sep 30, 2025Nov 25, 2025

-$0.04est. -$0.04

+$0.00

Not on file

Jun 30, 2025Aug 26, 2025

-$0.09est. -$0.06

-$0.03

Not on file

Mar 31, 2025May 15, 2025

-$0.04est. -$0.06

+$0.02

Not on file

Sep 30, 2024Nov 14, 2024

-$0.05Reported

No estimate

Not on file

NervGen Pharma Corp.

Smart money at a glance

What do analysts expect?

Questions about NGEN filings

Questions about NGEN filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

NervGen Pharma Corp.

Smart money at a glance

What do analysts expect?

Questions about NGEN filings

Questions about NGEN filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

NervGen Pharma Corp.

Overview

Questions about NGEN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

NervGen Pharma Corp.

Overview

Questions about NGEN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.